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Incretins, hormones released by the gut after meal
ingestion, are essential for maintaining systemic
glucose homeostasis by stimulating insulin secre-
tion. The effect of incretins on insulin secretion oc-
curs only at elevated glucose concentrations and
is mediated by cAMP signaling, but the mecha-
nism linking glucose metabolism and cAMP action
in insulin secretion is unknown. We show here, us-
ing a metabolomics-based approach, that cyto-
solic glutamate derived from the malate-aspartate
shuttle upon glucose stimulation underlies the
stimulatory effect of incretins and that glutamate
uptake into insulin granules mediated by cAMP/
PKA signaling amplifies insulin release. Glutamate
production is diminished in an incretin-unrespon-
sive, insulin-secreting b cell line and pancreatic is-
lets of animal models of human diabetes and
obesity. Conversely, a membrane-permeable gluta-
mate precursor restores amplification of insulin
secretion in these models. Thus, cytosolic gluta-
mate represents the elusive link between glucose
metabolism and cAMP action in incretin-induced
insulin secretion.CINTRODUCTION
Insulin secretion from pancreatic b cells is precisely regulated
by various intracellular signals to maintain blood glucose levels
within a normal range. Impaired insulin secretion contributes to
the pathogenesis and pathophysiology of diabetes (Polonsky
et al., 1988; Porte, 1991) and is a target for its treatment. Ac-
cording to the consensus model of glucose-induced insulin
secretion (GIIS), GIIS depends on a series of carefully orches-
trated b cell responses: mitochondrially generated ATP results
in closure of ATP-sensitive K+ (KATP) channels, which in turn trig-
gers membrane depolarization, electrical activity, and opening
of voltage-dependent Ca2+ channels (VDCCs), with the resultant
elevation of [Ca2+]i initiating Ca
2+-induced insulin granule
exocytosis (Henquin, 2000). Thus, ATP produced by glucose
metabolism is a critical signal in GIIS.
Pancreatic b cells are equipped with two highly active NADH
shuttles linked to glycolysis: the malate-aspartate shuttle and
the glycerol phosphate shuttle, both of which contribute to ATP
production. Whereas inhibition of either one of the NADH shuttles
does not affect GIIS, inhibition of both shuttles abolishesGIIS (Eto
et al., 1999). In addition, other intracellular signals in pancreatic
b cells, including cAMP and phospholipid-derived molecules
such as inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG), which are evoked by various nutrients and hormonal and
neuronal inputs, exert important modulatory functions of insulin
secretion in the maintenance of systemic glucose homeostasis.ell Reports 9, 661–673, October 23, 2014 ª2014 The Authors 661
(legend on next page)
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Incretins such as glucagon-like peptide 1 (GLP-1) and glu-
cose-dependent insulinotropic polypeptide (GIP) are secreted
by the enteroendocrine L cells and K cells, respectively, in
response to meal ingestion (Cataland et al., 1974; Kreymann
et al., 1987) and are critical for preventing postprandial hypergly-
cemia by amplifying insulin secretion through cAMP signaling
(Drucker, 2006; Holst, 2007). It is well known that incretin/
cAMP signaling stimulates insulin secretion in a glucose-depen-
dent manner (Siegel and Creutzfeldt, 1985; Prentki and Mat-
schinsky, 1987; Weir et al., 1989). Importantly, type 2 diabetes
is associated with impaired incretin-induced insulin secretion
(Nauck et al., 1993; Seino et al., 2010). The identification of the
amplifying effect of incretins in insulin secretion has paved the
way for recently developed incretin-based diabetes therapies
that carry less risk for hypoglycemia (Ahre´n, 2009; Drucker and
Nauck, 2006).
Recent studies have shown that incretin/cAMP signaling in
insulin secretion involves both protein kinase A (PKA)- and
Epac2A-dependent pathways (Seino and Shibasaki, 2005).
PKA phosphorylates various proteins associated with the insulin
secretory process, such as Snapin (Song et al., 2011), MyRIP,
Rabphilin (Brozzi et al., 2012), and Rip11 (Sugawara et al.,
2009). On the other hand, Epac2A, which contains a guanine
nucleotide exchange factor domain, activates the small G-
proteins Rap1 and Rap2 upon cAMP binding (Bos, 2006).
Epac2A/Rap1 signaling plays a key role in incretin-induced insu-
lin secretion, likely by promoting recruitment of insulin granules
and/or fusion events of the granules to the plasma membrane
(Shibasaki et al., 2007; Seino et al., 2011) or granule fusion itself
(Eliasson et al., 2003).
Glucose metabolism in pancreatic b cells is essential for both
triggering insulin secretion by glucose and amplifying insulin
secretion by incretin/cAMP signaling, but the mechanism of
the link between glucose metabolism and incretin/cAMP action
in insulin secretion has not been elucidated. Here, we employed
a differential metabolomics-based approach to address this
issue using incretin-responsive and -unresponsive b cell lines.
We find that cytosolic glutamate derived from the malate-aspar-
tate shuttle upon glucose stimulation is transported into insulin
granules by cAMP/PKA signaling, which leads to amplification
of insulin granule exocytosis. Our data highlight the role of cyto-
solic glutamate as a key signal linking glucose metabolism to in-
cretin/cAMP action to amplify insulin secretion.Figure 1. Distinct Profiles of Glucose Metabolism in Incretin-Respons
(A) Insulin secretory responses to glucose alone and glucose plus GLP-1 in MIN
(B) Metabolomic profiles expressed as a heatmap in MIN6-K8 and MIN6-K20 ce
(C) Univariate analysis of metabolome data on MIN6-K8 and MIN6-K20 cells und
values and fold changes are shown as a volcano plot. Each dot indicates a metab
significant [p < 0.05: -Log10 (p value) > 1.3] difference between the two cell lines are
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(D) Contents of metabolites showing the difference betweenMIN6-K8 andMIN6-K
also the legend to (C).
(E) Schematic view of how the two NADH shuttles (malate-aspartate shuttle a
a difference between MIN6-K8 and MIN6-K20 cells are indicated in red. a-KG
dihydroxyacetone phosphate; F6P, fructose 6-phophate; FBP, fructose 1,6-b
glyceraldehyde 3-phosphate; GLU, glutamate; MAL, malate; OAA, oxaloacetate
The data are expressed as means ± SEM. Results are representative of three in
significance (C and D). *p < 0.05; **p < 0.01. See also Table S1 and Figure S1.
CRESULTS
Profiles of Glucose Metabolism Differ between
Incretin-Responsive and -Unresponsive Mouse
Pancreatic b Cell Lines
Weutilized two recently establishedb cell lines, designatedMIN6-
K8 and MIN6-K20 cells (Iwasaki et al., 2010), as incretin-respon-
sive and -unresponsive b cell models, respectively, to investigate
the mechanism of incretin-induced insulin secretion. Like primary
pancreatic b cells, MIN6-K8 cells secrete insulin in response to
both glucose and the incretins GLP-1 and GIP, whereas MIN6-
K20 cells respond to glucose, but not to the incretins (Figures 1A,
S1A, and S1B). We ascertained the integrity of downstream
cAMP signaling targets of cAMP (PKA and Epac2A, as assessed
by phosphorylation of cAMP response element-binding protein
[CREB] or Rap1 activity, respectively) in both MIN6-K8 and
MIN6-K20 cells (Figures S1C and S1D). Likewise, no differences
in the capacity for cAMP production in response to GLP-1 or
GIP in these cells were detected (Iwasaki et al., 2010). These
findings indicate that the difference in incretin responsiveness be-
tweenMIN6-K8 andMIN6-K20 cells is not due to disruption of the
incretin/cAMP signaling pathways. Since incretin-induced insulin
secretion is glucose dependent, we considered the possibility
that the impaired incretin responsiveness of MIN6-K20 cells re-
sults from compromised ‘‘metabolism-cAMP coupling.’’ We ad-
dressed this possibility by conducting a metabolome analysis of
MIN6-K8 and MIN6-K20 cells stimulated by glucose (16.7 mM)
(Table S1). Hierarchical cluster multivariate analysis revealed
that MIN6-K8 and MIN6-K20 cells were separated into two
distinct clusters, indicating differences in the metabolic response
to glucose stimulation (Figure 1B). Univariate analysis (fold
change and t test) showed that the contents of glucose 6-phos-
phate (G6P), fructose 6-phosphate (F6P), fructose 1,6-bisphos-
phate (FBP), NADH, glutamate (GLU), and aspartate (ASP) were
significantly higher in MIN6-K8 cells than in MIN6-K20 cells (Fig-
ures 1C and 1D; Table S1). These results suggest higher activity
of the malate-aspartate shuttle in incretin-responsive MIN6-K8
cells than in incretin-unresponsive MIN6-K20 cells (Figure 1E).
Essential Role of the Malate-Aspartate Shuttle
in Incretin-Induced Insulin Secretion
We then examined the role of the malate-aspartate shuttle in
GIIS and incretin-induced insulin secretion (as assessed byive (MIN6-K8) and -Unresponsive (MIN6-K20) Cells
6-K8 (left) and MIN6-K20 (right) cells (n = 5–8 for each point).
lls under the glucose (16.7 mM)-stimulated condition (n = 3 for each).
er the glucose (16.7 mM)-stimulated condition (n = 3 for each). Welch’s t test p
olite. Metabolites showing a >2-fold [rLog2 (fold change)r > 1)] and statistically
indicated in red. ALA, alanine; ASP, aspartate; F6P, fructose 6-phophate; FBP,
alate.
20 cells under the glucose (16.7 mM)-stimulated condition (n = 3 for each). See
nd glycerol phosphate shuttle) are linked to glycolysis. Metabolites showing
, a-ketoglutarate; ASP, aspartate; BPGA, 1,3-bisphosphoglycerate; DHAP,
isphosphate; G3P, glycerol 3-phosphate; G6P, glucose 6-phosphate; GAP,
. See also the legend to (C).
dependent experiments. Welch’s t test was used for evaluation of statistical
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Figure 2. Essential Role of the Malate-
Aspartate Shuttle in Incretin-Induced Insulin
Secretion
(A) Malate-aspartate shuttle. Aralar1, aspartate/
glutamate carrier; AST1 and AST2, aspartate
aminotransferase 1 and 2, respectively. See also
the legend to Figure 1E.
(B and C) Effect of AOA, an inhibitor of the malate-
aspartate shuttle, on insulin secretion from MIN6-
K8 cells (B) and mouse pancreatic islets (C). The
concentrations of AOA used were 2.5 mM inMIN6-
K8 cells and 5 mM in mouse pancreatic islets.
(D–F) Effects of KD of AST1 (D), AST2 (E), and
Aralar1 (F) on insulin secretion fromMIN6-K8 cells.
(G) Glycerol phosphate shuttle. GPD1 and GPD2,
glycerol 3-phosphate dehydrogenase 1 and 2,
respectively. See also the legend to Figure 1E.
(H and I) Effects of KD of GPD1 (H) and GPD2 (I) on
insulin secretion from MIN6-K8 cells.
The data are expressed as means ± SEM (n = 4–8).
Results are representative of three independent
experiments. Welch’s t test was used for evalua-
tion of statistical significance. *p < 0.05; **p < 0.01;
n.s., not significant. See also Figure S2.amplification of insulin secretion by GLP-1 and GIP) by using
aminooxyacetate (AOA), an inhibitor of the shuttle (Eto et al.,
1999; MacDonald, 1982; Figure 2A). We found that AOA did
not affect GIIS but virtually abolished the response to GLP-1 or
GIP in MIN6-K8 cells (Figure 2B). Very similar observations
were made in primary mouse pancreatic islets treated with
AOA (Figure 2C). These results suggest that whereas activity of
the malate-aspartate shuttle is essential for incretin-induced in-
sulin secretion, this is not the case for GIIS. To further confirm
the role of the malate-aspartate shuttle, we next examined the
effects of knockdown (KD) of the aspartate aminotransferases
AST1 and AST2 or the aspartate/glutamate carrier Aralar1 on in-
sulin secretion in MIN6-K8 cells. As illustrated schematically in
Figure 2A, these enzymes are all required for malate-aspartate
shuttle activity. Reduced expression of AST1 (68%; Fig-
ure S2A), AST2 (83%; Figure S2B), or Aralar1 (93%; Fig-
ure S2C) did not affect GIIS, but decreased incretin-induced
insulin secretion (Figures 2D–2F). By contrast, KD of glycerol
3-phosphate dehydrogenases GPD1 (52%; Figure S2E) or
GPD2 (80%; Figure S2F), both of which are required for activity
of the glycerol phosphate shuttle (another NADH shuttle that is664 Cell Reports 9, 661–673, October 23, 2014 ª2014 The Authorslinked to glycolysis; Figure 2G), affected
neither GIIS nor incretin-induced secre-
tion (Figures 2H and 2I). The possibility
that AOA has effects on other transami-
nases was ruled out by KD experiments
with branched-chain aminotransferase
2 (BCAT2) and alanine aminotransferase
2 (ALT2) (Figures S2H–S2K). We ascer-
tained that KD of these enzymes/carrier
did not affect cellular insulin content (Fig-
ures S2D, S2G, and S2L). Thus, while GIIS
is maintained following abolition of either
the malate-aspartate or glycerol phos-phate shuttle, incretin-induced insulin secretion depends exclu-
sively on the malate-aspartate shuttle.
Glucose-Dependent Production of Cytosolic Glutamate
and cAMP/PKA-Dependent Glutamate Transport into
Insulin Granules
We next attempted to clarify the relationship between the ma-
late-aspartate shuttle and incretin stimulation. We first consid-
ered direct incretin-induced activation of the shuttle. However,
metabolome analysis revealed (with the exception of cAMP; Ta-
ble S2) no differences in the contents of the metabolites associ-
ated with glycolysis and themalate-aspartate shuttle inMIN6-K8
cells stimulated by glucose (16.7 mM) alone or glucose plus
GLP-1 (10 nM or 100 nM). In addition, the activities of AST1
and malate dehydrogenase MDH1, both of which are required
for malate-aspartate shuttle activity (Figure S3A), were not
increased by GLP-1 (Figures S3B and S3C). These results indi-
cate that incretin-induced insulin secretion is not caused by
direct activation of the malate-aspartate shuttle. We therefore
explored the alternative possibility that a metabolite associated
with the malate-aspartate shuttle mediates the effect on insulin
secretion. We focused on glutamate since it was increased in
response to glucose in incretin-responsive MIN6-K8 cells and
was previously proposed to be a signal in insulin secretion (Mae-
chler and Wollheim, 1999). Cytosolic glutamate is converted
from a-ketoglutarate through the malate-aspartate shuttle
upon glucose stimulation (Figure 2A). We therefore hypothesized
that cytosolic glutamate might mediate incretin-induced insulin
secretion. Total cellular glutamate content was increased in a
glucose-concentration-dependent manner, but was not affected
by GLP-1 (Figure 3A). a-Ketoglutarate content also was in-
creased by glucose stimulation (Figure S3D). We next used
mass spectrometry to determine 13C enrichment of glutamate
in MIN6-K8 cells exposed to [U-13C]-glucose. The cytosolic con-
tents of M and M+1 glutamate isotopomers (no substitution with
13C derived from [U-13C]-glucose), both of which are naturally
existing in cells, were unchanged by glucose stimulation,
whereas M+2, M+3, M+4, and M+5 glutamate isotopomers
(two to five 13C substitutions for 12C) were increased significantly
(Figures 3B and 3C). GLP-1 did not alter the distribution of gluta-
mate isotopomers produced by glucose.
We then investigated the involvement of the malate-aspartate
shuttle in glutamate production using preparations of whole cells
and cytosolic and mitochondrial fractions of MIN6-K8 cells with
or without AOA treatment. We found that cytosolic glutamate
contributed to the majority of cellular glutamate under glucose
stimulation and that treatment with AOA markedly suppressed
the production of both cellular and cytosolic glutamate (Figures
3D–3F and S3E). In addition, neither GIIS nor incretin-induced in-
sulin secretion was affected by KD of glutamate dehydrogenase
1 (GDH1; 72%; Figures S3F–S3H), the enzyme that catalyzes
the production of mitochondrial glutamate from a-ketoglutarate.
Together, these results suggest that glucose increases cytosolic
glutamate through the malate-aspartate shuttle.
Importantly, glutamate content in insulin granules was not
increased by glucose (16.7 mM) alone, but was increased signif-
icantly by the addition of GLP-1 (Figures 3G and S3I). The in-
crease in granular glutamate content by GLP-1 was blocked
by H-89, a PKA inhibitor, whereas the glutamate content was
not increased by 8-pCPT-20-O-Me-cAMP-AM, an Epac-selec-
tive cAMP analog (Figure 3G), indicating that glutamate content
in insulin granules is increased by a cAMP/PKA-dependent
mechanism. By analyzing 13C-enriched glutamate using
[U-13C]-glucose as a substrate, we confirmed that GLP-1
increased the amounts of M+2 to M+5 glutamate isotopomers
(two to five 13C substitutions for 12C) in insulin granules in a con-
centration-dependent manner (Figure 3H), a finding that is
consistent with the effect of GLP-1 on insulin secretion (Fig-
ure S3J). These results suggest that cytosolic glutamate derived
from a-ketoglutarate through themalate-aspartate shuttle repre-
sents a signal that mediates incretin-induced insulin secretion.
Glutamate as a Signal in Incretin-Induced
Insulin Secretion
To clarify whether glutamate acts as a signal in incretin-induced
insulin secretion, we next investigated the role of glutamate in
cAMP-induced insulin granule exocytosis. We examined the ef-
fect of increasing concentrations of cytosolic glutamate on
depolarization-evoked exocytosis in pancreatic b cells usingCthe standard whole-cell technique in conjunction with mea-
surements of membrane capacitance (DCm) (Rorsman and Re-
nstro¨m, 2003) in the absence and presence of cAMP. Whereas
glutamate (3 and 10 mM) stimulated exocytosis in the absence
of cAMP, consistent with previous reports (Høy et al., 2002),
the effect was minute compared with the much stronger amplifi-
cation seen in the presence of cAMP (Figure 4A). The effect of
glutamate on exocytosis in the presence of 100 mM cAMP was
not mimicked by malate (10 mM; data not shown). Exocytosis
evoked by glutamate in the presence of cAMP was inhibited by
application of PKI (10 mM), a PKA-inhibitory peptide (Figure 4B).
Together with the finding that the increase in glutamate content
in insulin granules by GLP-1 was blocked by H-89 (Figure 3G),
these results indicate that glutamate acts as a signal in cAMP-
induced exocytosis in a PKA-dependent manner.
To further confirm that glutamate acts as an amplifying signal
in insulin secretion, we examined the effect of dimethyl-glu-
tamate, a membrane-permeable glutamate precursor (Mae-
chler and Wollheim, 1999). We found that dimethyl-glutamate
is converted to glutamate in insulin granules as well as in the
cytosol (Figures S4A and S4B), as assessed by analysis of
13C-enriched glutamate in MIN6-K8 cells. Dimethyl-glutamate
amplified both the first and second phases of glucose-induced
insulin granule exocytosis (analyzed by total internal reflection
fluorescence microscopy [TIRFM]) (Shibasaki et al., 2007; Fig-
ures 4C and S4C). In incretin-unresponsive MIN6-K20 cells,
cytosolic glutamate content was not increased at all by glucose
(Figure 4D), but dimethyl-glutamate markedly amplified insulin
secretion (Figure 4E). As dimethyl-malate and dimethyl-succi-
nate have no effects on insulin secretion (Figures S4D and
S4E), it is unlikely that dimethyl-glutamate is used as a fuel to
stimulate insulin secretion. These results indicate that
dimethyl-glutamate mimics the effect of incretin/cAMP on insu-
lin secretion. Collectively, these findings corroborate the view
that glutamate acts as an amplifying signal in incretin-induced
insulin secretion.
Requirement of Glutamate Transport into Insulin
Granules for Amplification of Insulin Secretion by
Incretin/cAMP Signaling
Glutamate is transported into secretory vesicles in neurons (Naito
and Ueda, 1983) and enteroendocrine cells (Uehara et al., 2006)
through vesicular glutamate transporters (VGLUTs) (Bellocchio
et al., 2000; Gras et al., 2002; Omote et al., 2011; Takamori
et al., 2001). VGLUT1, VGLUT2, and VGLUT3 are expressed in
the pancreatic b cell lines bTC6, RINm5F, and INS-1E, and their
insulin granules have the capacity to accumulate glutamate (Bai
et al., 2003; Gammelsaeter et al., 2011). Analysis by quantitative
real-time RT-PCR showed that VGLUT1 is the predominant
VGLUT in MIN6-K8 cells (Figure 5A). Immunocytochemical and
immunoblot analyses revealed that VGLUT1 colocalizes with in-
sulin granules (Figures 5B and 5C). We then examined the role
of glutamate transport into insulin granules in insulin secretion us-
ing Evans blue, an inhibitor of glutamate transport into secretory
vesicles (Maechler and Wollheim, 1999; Roseth et al., 1995), and
KD of VGLUT1 (94%; Figure S5A). The two procedures yielded
identical responses: GIIS was not affected, but the incretin-
induced stimulation was abolished (Figures 5D and 5E). Byell Reports 9, 661–673, October 23, 2014 ª2014 The Authors 665
Figure 3. Glucose-Dependent Production of Cytosolic Glutamate and Increased Glutamate Contents in Insulin Granules by cAMP/PKA
Signaling
(A) Effect of glucose on total cellular glutamate contents in the absence or presence of GLP-1 (10 nM) in MIN6-K8 cells (n = 3 for each point).
(B and C) Changes in contents of glutamate isotopomers (M to M+5) by glucose stimulation in the absence or presence of GLP-1 (10 nM) in whole cells (B) and
cytosol (C) in MIN6-K8 cells (n = 4–5 for each).
(D–F) Effects of AOA on contents of glutamate isotopomers (M+2 to M+5) in whole cells (D), cytosol (E), and mitochondria (F) in MIN6-K8 cells (n = 3 for each).
(G) Effects of glucose, GLP-1 (10 nM), H-89 (10 mM, a PKA inhibitor), and 8-pCPT (10 mM, 8-pCPT-20-O-Me-cAMP-AM, an Epac-selective cAMP analog) on
glutamate contents in insulin granules in MIN6-K8 cells (n = 4–12).
(H) Dose-dependent effects of GLP-1 on glutamate contents in insulin granules inMIN6-K8 cells under the glucose (11.1mM)-stimulated condition (n = 4 for each).
The data are expressed as means ± SEM. Results are representative of three independent experiments. The Tukey-Kramer method was used for evaluation of
statistical significance. *p < 0.05; **p < 0.01; n.s., not significant. See also Table S2 and Figure S3.
666 Cell Reports 9, 661–673, October 23, 2014 ª2014 The Authors
Figure 4. Glutamate as a Signal in Incretin-
Induced Insulin Granule Exocytosis
(A) Effect of intracellular glutamate on exocytosis.
Exocytosis (DCm) wasmeasured in a singlemouse b
cell at concentrations of 0, 1, 3, and 10 mM intra-
cellular glutamate (added via the recording elec-
trode) in the presence or absence of 100 mM cAMP
(n = 19–31 for eachpoint). Exocytosiswas elicitedby
trains of four 500msdepolarizations from70mV to
zero mV applied at 1 Hz (indicated schematically in
the upper-left corner). All data points in the presence
of cAMP are significantly different from corre-
sponding values in the absence of cAMP (p < 0.05 or
better). Glutamate (3 and 10 mM) stimulates
exocytosis in both the absence and presence of
cAMP as compared with the relative control (no
glutamate), but responses in the absence of cAMP
are dwarfed compared with the much larger effects
in the presence of cAMP. **p < 0.01 versus no
glutamate in the absence or presence of cAMP.
(B) Effect of PKI (10 mM), a PKA-inhibitory peptide,
on exocytosis. Exocytosis (DCm) was measured in
a single mouse b cell in the presence of 3 mM
glutamate in cells exposed to 10 and 100 mMcAMP
as indicated (n = 20–27).
(C) Effect of dimethyl-glutamate (dm-glutamate), a
membrane-permeable glutamate precursor, on
insulin granule exocytosis. The exocytosis was
measured as fusion events by TIRFM. Histograms
show the number of fusion events caused by
glucose alone (left) and glucose plus dimethyl-
glutamate (right) in primary cultured mouse
pancreatic b cells (n = 4 for each); ‘‘2.8’’ indicates
2.8 mM glucose.
(D) Effect of glucose on cytosolic glutamate pro-
duction in incretin-unresponsive MIN6-K20 cells
(n = 7–8 for each point).
(E) Effect of dimethyl-glutamate (dm-glutamate) on
insulin secretion from incretin-unresponsive MIN6-
K20 cells (n = 4–8 for each).
The data are expressed asmeans ±SEM. Results are representative of three independent experiments. Student’s t test (A and B) and Dunnett’s method (D and E)
were used for evaluation of statistical significance. **p < 0.01; n.s., not significant. See also Figure S4.contrast, KD of VGLUT2 (71%; Figure S5B) affected neither
GIIS nor incretin-induced insulin secretion (Figure 5F), and KD
of either VGLUT did not affect cellular insulin content (Figures
S5C and S5D). Dynamic measurements of insulin secretion
demonstrated that the amplification by GLP-1 of both the first
and second phases of insulin secretion in MIN6-K8 cells was
strongly inhibited by KD of VGLUT1 (Figure S5E). We also exam-
ined insulin secretion from the pancreatic islets of VGLUT1
knockout (Slc17a7/) mice. GIIS did not differ between wild-
type (Slc17a7+/+) and Slc17a7/ islets, but the stimulatory effect
of GLP-1 was not seen in Slc17a7/ islets (Figure 5G). Impor-
tantly, dimethyl-glutamate restored amplification of insulin secre-
tion in Slc17a7/ mice (Figure 5G).
We next examined the potential role of V-ATPase, which has
been shown to participate in vesicular glutamate transport
(Omote et al., 2011), in insulin secretion in MIN6-K8 cells. Neither
KD of V-ATPase subunit D (69%; Figure S5F) nor bafilomycin,
an inhibitor of V-ATPase, affected GIIS, but both reduced the
amplification evoked by GLP-1 (Figures 5H and 5I) without
affecting cellular insulin content (Figure S5G). Intriguingly,Cdimethyl-glutamate restored insulin secretion in the bafilomy-
cin-treated MIN6-K8 cells (Figure 5I). These results indicate
that glutamate transport into insulin granules through VGLUT1
is required for incretin-induced insulin secretion.
Pathophysiological Role of Glutamate in Insulin
Secretion
To clarify the relationship between glutamate production and
insulin secretion in disease states, we compared GIIS and incre-
tin-induced insulin secretion in nondiabetic Wistar, diabetic
Goto-Kakizaki (GK) (Goto et al., 1975), and obese Zucker fatty
(ZF) rats (Zucker and Zucker, 1961). TheGK rat is amodel of non-
obese type 2 diabetes with defective insulin secretion associ-
ated with impaired glucose metabolism in pancreatic b cells
(Ostenson et al., 1993). Although GIIS from the pancreatic islets
of GK rats was markedly decreased compared with that of Wis-
tar rats (Figures 6A, 6B, and S6A), the incretins retained their
amplifying capacity. Dimethyl-glutamate also amplified insulin
secretion in GK rats. In contrast, in ZF rats, a model of obesity
with a mutation in the leptin receptor gene, basal insulinell Reports 9, 661–673, October 23, 2014 ª2014 The Authors 667
Figure 5. Requirement of Glutamate Transport into Insulin Granules for Amplification of Insulin Secretion by Incretin/cAMP Signaling
(A) mRNA expression levels of VGLUTs in MIN6-K8 cells (n = 3–4 for each). n.d., not detected.
(B) Immunocytochemical analysis of VGLUT1 in MIN6-K8 cells and pancreatic islets. Scale bars, 10 mm.
(C) Immunoblot analysis of VGLUT1 in insulin granules in MIN6-K8 cells. The insulin granule fraction was confirmed by immunoblot analysis using anti-PC1/3
antibody.
(D) Effect of Evans blue, an inhibitor of vesicular glutamate transport, on insulin secretion from MIN6-K8 cells (n = 5–8 for each).
(E and F) Effects of KD of VGLUT1 (E) and VGLUT2 (F) on insulin secretion from MIN6-K8 cells (n = 4–8 for each).
(G) Insulin secretion from pancreatic islets of wild-type (Slc17a7+/+) and VGLUT1 knockout (Slc17a7/) mice (n = 4–8 for each). dm-glutamate, dimethyl-
glutamate.
(H) Effect of KD of V-ATPase subunit D on insulin secretion from MIN6-K8 cells (n = 4 for each).
(I) Effect of bafilomycin, an inhibitor of V-ATPase, on insulin secretion from MIN6-K8 cells (n = 4 for each).
The data are expressed as means ± SEM. Results are representative of three independent experiments. Welch’s t test (D–F, H, and I) and Dunnett’s method (G)
were used for evaluation of statistical significance. *p < 0.05; **p < 0.01; n.s., not significant. See also Figure S5.
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Figure 6. Pathophysiological Role of Gluta-
mate in Insulin Secretion
(A–C) Insulin secretion from pancreatic islets of
Wistar (A, n = 8 for each), GK (B, n = 6 for each), and
ZF (C, n = 8 for each) rats. The inset in the middle
panel (B) is included to magnify the scale of the y
axis in GK rats. The concentrations of dm-gluta-
mate used were 10 mM, 10 mM, and 50 mM for
Wistar, GK, and ZF rats, respectively.
(D) Production of glutamate isotopomers (M+2 to
M+5) by glucose stimulation in pancreatic islets of
Wistar, GK, and ZF rats (n = 3 for each).
The data are expressed as means ± SEM. Results
are representative of three independent experi-
ments. Dunnett’s method (A–C) and Welch’s t test
(D) were used for evaluation of statistical signifi-
cance. *p < 0.05; **p < 0.01; n.s., not significant.
See also Figure S6.secretion was already high compared with the control, but signif-
icant GIIS occurred (Figures 6C and S6B). Unlike Wistar and GK
rats, adult ZF rats (R12 weeks of age) exhibited no amplification
of insulin secretion in response to incretin stimulation, but
dimethyl-glutamate remained effective. We then examined
whether glucose-induced islet glutamate production is affected
in these rat models, as assessed by analysis of 13C-enriched
glutamate. Glucose stimulated glutamate production in GK
islets, but the levels were lower than those in Wistar islets (Fig-
ure 6D). By contrast, no glucose-stimulated glutamate produc-
tion was seen in ZF islets.
DISCUSSION
Using metabolome analysis by mass spectrometry, we found
that glucose increased cytosolic glutamate through the malate-
aspartate shuttle and that GLP-1 promoted glutamate transport
into insulin granules via cAMP/PKA signaling. We also found that
glutamate in insulin granules stimulated insulin secretion, as as-
sessed by capacitance measurements, TIRFM analysis, and
VGLUT1 knockout and KD experiments. Glutamate thus acts
as a key cell signal linking glucose metabolism to incretin/Cell Reports 9, 661–673cAMP action to amplify insulin secre-
tion. Figure 7 summarizes these findings
schematically.
It is well established that incretins and
agents that elevate intracellular cAMP
amplify insulin secretion but are unable
to initiate insulin secretion on their own.
The amplifying effect is not mediated
by enhanced glucose metabolism, i.e.,
increased ATP production (Brisson et al.,
1972; Peyot et al., 2009), and the nature
of the molecular link between glucose
metabolism and incretin/cAMP signaling
in amplification of insulin secretion re-
mains elusive. To clarify this, we per-
formed a metabolome analysis using
capillary electrophoresis-mass spectrom-etry (CE-MS), which can detect and quantify metabolites,
including the intermediate metabolites in glycolysis and the
TCA cycle, amino acids, and nucleic acids. Based on our find-
ings that GLP-1 has little or no effect on the amounts of metab-
olites in glucose metabolism (glycolysis, TCA cycle, pentose
phosphate pathway, glycogenesis, and NADH shuttles) or the
activities of enzymes in the malate-aspartate shuttle, we can
discard the possibility that incretin/cAMP signaling exerts a
direct effect on glucose metabolism.
Using differential metabolomics, we compared metabolites
associated with glucose metabolism between incretin-respon-
sive and -unresponsive b cell lines. Based on the finding that in-
hibition of the malate-aspartate shuttle blocked incretin-induced
insulin secretion, we focused on the metabolites derived from
the shuttle. Among them, glutamate attracted our attention.
Mitochondrial glutamate (produced byGDH) was previously pro-
posed to act as a signal in GIIS (Maechler and Wollheim, 1999;
Høy et al., 2002; Casimir et al., 2009), although this has been
controversial and some observations seem inconsistent with
the notion (Bertrand et al., 2002; MacDonald and Fahien,
2000). In the present study, we found that 72% KD of GDH1 (at
the mRNA level) did not affect GIIS in MIN6-K8 cells. However,, October 23, 2014 ª2014 The Authors 669
Figure 7. Glutamate Acts as a Key Signal in Amplification of Insulin
Secretion by Incretin/cAMP Signaling
Glutamate links glucose metabolism and incretin/cAMP signaling to amplify
insulin secretion. See text for the details. GP shuttle, glycerol phosphate
shuttle; MA shuttle, malate-aspartate shuttle; KATP channel, ATP-sensitive K
+
channel; VDCC, voltage-dependent Ca2+ channel.we cannot rule out the possibility that mitochondrial glutamate is
involved in GIIS, since knockout of GDH1 inmice decreasedGIIS
by 50% compared with control (Carobbio et al., 2009; Vetterli
et al., 2012). On the other hand, the role of cellular glutamate in
amplification of insulin secretion by incretin/cAMP signaling
has not been investigated. We demonstrate here that cytosolic
glutamate derived from the malate-aspartate shuttle, which
represents a major fraction of cellular glutamate produced by
glucose, is crucial for incretin-induced insulin secretion. Mito-
chondrial glutamate may also contribute to a fraction of cytosolic
glutamate, as it is continuously exported to cytosol through GC1
(Casimir et al., 2009).
Our findings indicate that glutamate transport into the insulin
granules occurs only in cells exposed to the combination of
glucose and GLP-1, and not in cells exposed to glucose alone.
Indeed, inhibition of glutamate transport into the granules dimin-
ished incretin-induced insulin secretion, but did not affect GIIS.
Our data demonstrate that glutamate transport into insulin gran-
ules by cAMP signaling plays a decisive role in incretin-induced
insulin secretion. Although glucose induces cAMP production
(Charles et al., 1973; Grill and Cerasi, 1973; Dyachok et al.,
2008), it produces a much smaller amount of cAMP than does
GLP-1 (Delmeire et al., 2003; Iwasaki et al., 2010; Susini et al.,
1998). Thus, glucose-induced cAMP production is insufficient
(at least under the experimental conditions used in the present
study) to sustain sufficient glutamate transport into the insulin
granules, but under other experimental paradigms, this could
occur.
In neurons, glutamate transport into the synaptic vesicles
through VGLUTs is regulated by the electrical potential (D4)
and pH gradient (DpH) across the vesicular membrane (Omote
et al., 2011). A proton pump V-ATPase on insulin granules con-
tributes to generation of D4 and DpH across the insulin granule670 Cell Reports 9, 661–673, October 23, 2014 ª2014 The Authorsmembrane (Aspinwall et al., 1997), in which Cl flux is needed
(Xie et al., 1983; Xie et al., 1989). TheCl flux through the chloride
transport protein ClC-3 in the insulin granule membrane has
been shown to be required for GIIS (Li et al., 2009). In addition,
it was reported that glutamate flux in the insulin granules was
involved in the generation of D4 and DpH, and that perturbing
the flux decreased insulin granule exocytosis (Gammelsaeter
et al., 2011). We found that inhibition of either VGLUT1 or
V-ATPase did not affect GIIS, but reduced amplification of insulin
secretion by incretins. Furthermore, dimethyl-glutamate was
able to mimic the effects of incretins under the condition of
VGLUT1 deficiency or V-ATPase inhibition. These results indi-
cate that glutamate transport into insulin granules, which is
mediated by activation of cAMP/PKA signaling, is required for
amplification of insulin granule exocytosis. Although the precise
mechanism by which glutamate in insulin granules stimulates in-
sulin granule exocytosis remains to be elucidated, the finding by
TIRFM analysis that most of the insulin granule exocytosis
induced by dimethyl-glutamate is caused by granules that are
newly recruited and immediately fused to the plasma membrane
(Shibasaki et al., 2007) suggests that glutamate in insulin gran-
ules facilitates recruitment toward and/or fusion of the insulin
granules with the plasma membrane.
We also provide data implicating defective glutamate
signaling in the pathophysiology of insulin secretion in the GK
and ZF rat models of human diabetes and obesity, respectively.
In GK rats, amplification of insulin secretion by incretins was
much reduced, with amarked suppression of glutamate produc-
tion by glucose. In ZF rats, there was no amplification at all by
incretins, with no glutamate production. Importantly, dimethyl-
glutamate was able to amplify insulin secretion, mimicking the
effect of incretins, in all of these models. Thus, impaired produc-
tion of glutamate in pancreatic b cells could lead to a defect in
incretin-induced insulin secretion. Indeed, some reports have
suggested that incretin-based therapies have limited insulino-
tropic effects in clinical settings (Holst et al., 2011; Kubota
et al., 2012).
In summary, our data demonstrate that glutamate acts as a
key signal linking glucose metabolism and incretin/cAMP action
to amplify insulin secretion. Therefore, elucidating glutamate
signaling may not only clarify the pathophysiology of diabetes
mellitus but may also pave the way for novel therapeutic
strategies.
EXPERIMENTAL PROCEDURES
Animal Experiments
MaleWistar (Slc:Wistar), GK (GK/Slc), and ZF (Slc:Zucker, fa/fa) rats (10 weeks
old) were purchased from Japan SLC. VGLUT1 knockout (Slc17a7/) mice
were provided by R.H. Edwards. Animal experiments were approved by the
Committee on Animal Experimentation of Kobe University and carried out in
accordance with the Guidelines for Animal Experimentation at Kobe Univer-
sity. Electrophysiological experiments were performed on b cells from NMRI
mice and the experiments were conducted in accordance with the Animals
(Scientific Procedures) Act 1986 and ethical guidelines of the University of
Alberta and University of Oxford.
Metabolome Analysis
Hydrophilic metabolites were extracted fromMIN6-K cells and then subjected
to CE-MS. See Supplemental Experimental Procedures for details.
Insulin Secretion
Insulin-secretion experiments on MIN6-K cells and pancreatic islets were
performed as previously described (Yasuda et al., 2010). See Supplemental
Experimental Procedures for details.
KD Experiments
MIN6-K8 cells were infected with small interfering RNA (siRNA) or adenovirus
carrying short hairpin RNA (shRNA). See Supplemental Experimental Proce-
dures for details.
mRNA Expression
Isolation of total RNA and quantitative real-time RT-PCR were performed as
previously described (Matsubara et al., 2012), with 18S ribosomal RNA used
as an internal control.
Glutamate Contents
Glutamate contents in lysed cells were determined with the use of the L-Gluta-
mate Assay Kit II (Yamasa). The contents of glutamate isotopomers were also
measured by 13C-enrichment analysis, with uniformly labeled [U-13C]-glucose
as a substrate, using CE-MS. See Supplemental Experimental Procedures for
details.
Electrophysiology
Capacitance recordings of single b cell exocytosis were obtained essentially
as described previously (Kanno et al., 2004). See Supplemental Experimental
Procedures for details.
Immunofluorescence Staining
Immunofluorescence staining was performed as previously described (Ya-
suda et al., 2010). See Supplemental Experimental Procedures for details.
TIRFM Analysis
TIRFM analysis was performed as previously described (Shibasaki et al.,
2007).
Statistical Analysis
The data are expressed as means ± SEM. Statistical comparisons were made
usingWelch’s t test, Student’s t test, Dunnett’smethod, and the Tukey-Kramer
method as indicated in the figure legends. Differences for which the p value
was <0.05 were regarded as statistically significant. Hierarchical cluster anal-
ysis (average linkage) was performed on Pareto-scaled metabolomics data
(distance measures based on the Pearson correlation) using Multiple Experi-
ment Viewer (MeV) (Saeed et al., 2003).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.09.030.
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